Blood test shows promise for predicting pancreatic cancer survival

Researchers identified a simple plasma biomarker that could help doctors predict which pancreatic cancer patients will survive longer. The finding could reshape treatment decisions and clinical trial design, potentially allowing physicians to tailor therapies and identify patients most likely to benefit from aggressive intervention.

Originaltitel: Plasma thymidine kinase activity as a prognostic biomarker in pancreatic ductal adenocarcinoma: a single-center prospective study